Aug. 18, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung can

Eli Lilly has tapped OmniAb and its antibody discovery engine for an ion channel-focused collaboration. While the deal is light on details, the California-based research firm will receive an undisclosed upfront payment and is eligible for up to $370 million in R&D and commercial milestones, plus tiered royalties. The licensing agreement covers a new ion channel programme with an undisclosed target and modality, though it's likely to be antibody-based given OmniAb specialises in antibody discove

Sandoz and Shanghai Henlius Biotech are expanding their existing oncology biosimilars partnership in a deal that could generate up to $322 million for the Chinese drugmaker. The strategic tie-up covers up to 10 proposed monoclonal antibody and antibody-drug conjugate biosimilars, with a majority of the programmes still in early development. Under the deal announced Monday, Sandoz will receive exclusive rights to register and commercialise the partnered products outside China. Henlius, using it

Khartis said the financing would support its pipeline of oral small molecule medicines targeting immunology pathways. Credit: Maryia Blizniakova/Shutterstock.com. Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of bringing a new treatment for an autoimmune disease that causes eye inflammation. Unveiling itself via a $50m Series B raise announcement, Khartis said its pipeline includes oral small-molecule medicines with both

ANS-858 is being developed to reduce pathological craving associated with alcohol and other substance use disorders. Amygdala's ALDH2 inhibitor platform offers additional therapeutic opportunities in binge eating, obesity, and precision oncology. PALO ALTO, Calif., Aug. 18, 2026 /PRNewswire/ -- Amygdala Neurosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ANS-858, enabling the Company to adva

Aug. 18, 2026 -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced today that new data from a multi-institutional feasibility clinical trial across 15 institutions nationwide presented by Clark Chen, M.D., Ph.D., professor and director of the Brain Tumor Program at Brown University Health, suggest that a novel radiation therapy device may help improve outcomes for patients newly diagnosed with glioblastoma, one of th

Hoag Hospital joins Aqua Medical's multi-center RESTORE-I study as its Irvine Hoag team, led by Dr. Jennifer Phan, delivers a milestone procedure and Dr. Phan becomes the first woman interventional endoscopist in the U.S. to perform it. Aug. 18, 2026 -- Aqua Medical, Inc., a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration, today announced the treatment of the first West Coast patient (second overall in the US) in the company's FDA-approved Investigational De

Aug. 18, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors. HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Company's HBI

LEO Pharma is set to acquire exclusive global rights to dersimelagon (MT-7117), an investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), from Tanabe Pharma. As part of the deal announced Tuesday, LEO will pay Tanabe $435 million in upfront and near-term milestone payments, with the latter also eligible for additional downstream milestones, alongside tiered sales royalties. Dersimelagon is a once-daily, oral melanocortin 1 receptor (MC1R) agonist des

Shares in Amylyx Pharmaceuticals jumped more than 30% on Tuesday after the company reported that a Phase III study of avexitide in people with post-bariatric hypoglycaemia (PBH) met its primary endpoint, setting up an FDA filing for the GLP-1 receptor antagonist by the end of the year. "Together with the positive data generated across five previous clinical trials of avexitide in PBH, we believe the LUCIDITY results bring us one step closer to potentially delivering the first approved treatment